Literature DB >> 18562176

Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia.

Amy E Steffek1, Robert E McCullumsmith, Vahram Haroutunian, James H Meador-Woodruff.   

Abstract

Altered expression of structural and functional molecules expressed by astrocytes may play a role in the pathophysiology of schizophrenia. We investigated the hypothesis that the astrocytic enzyme glutamine synthetase, involved in maintaining the glutamate-glutamine cycle, and the cytoskeletal molecule glial fibrillary acidic protein (GFAP) are abnormally expressed in schizophrenia. We used Western blot analysis to measure levels of glutamine synthetase and GFAP in several brain regions of subjects with schizophrenia and a comparison group. We found that glutamine synthetase protein expression was significantly decreased in the superior temporal gyrus, and both glutamine synthetase and GFAP were significantly reduced in the anterior cingulate cortex in schizophrenia. Neither molecule demonstrated altered expression in the dorsolateral prefrontal cortex, primary visual cortex, or hippocampus. Chronic treatment with haloperidol did not alter the expression of these molecules in the rat brain, suggesting that our findings are not due to a medication effect. These data support an astrocytic component to the pathophysiology of schizophrenia and suggest that astrocytic molecules involved in enzymatic activity and cytoskeletal integrity may have a role in disease-related abnormalities in this illness.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18562176      PMCID: PMC3774017          DOI: 10.1016/j.schres.2008.04.032

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  77 in total

1.  Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter.

Authors:  E E Bellocchio; R J Reimer; R T Fremeau; R H Edwards
Journal:  Science       Date:  2000-08-11       Impact factor: 47.728

2.  Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes.

Authors:  Clare L Beasley; Kyla Pennington; Aine Behan; Robin Wait; Michael J Dunn; David Cotter
Journal:  Proteomics       Date:  2006-06       Impact factor: 3.984

3.  Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium.

Authors:  N L Johnston-Wilson; C D Sims; J P Hofmann; L Anderson; A D Shore; E F Torrey; R H Yolken
Journal:  Mol Psychiatry       Date:  2000-03       Impact factor: 15.992

4.  Effect of olanzapine treatment on platelet glutamine synthetase-like protein and glutamate dehydrogenase immunoreactivity in schizophrenia.

Authors:  Gulnur Sh Burbaeva; Irina S Boksha; Elena B Tereshkina; Olga K Savushkina; Marina S Turishcheva; Lubov I Starodubtseva; Oleg S Brusov; Margarita A Morozova
Journal:  World J Biol Psychiatry       Date:  2006       Impact factor: 4.132

5.  Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients.

Authors:  Stella Dracheva; Kenneth L Davis; Benjamin Chin; Derek A Woo; James Schmeidler; Vahram Haroutunian
Journal:  Neurobiol Dis       Date:  2005-10-05       Impact factor: 5.996

6.  The Alexander disease-causing glial fibrillary acidic protein mutant, R416W, accumulates into Rosenthal fibers by a pathway that involves filament aggregation and the association of alpha B-crystallin and HSP27.

Authors:  Ming Der Perng; Mu Su; Shu Fang Wen; Rong Li; Terry Gibbon; Alan R Prescott; Michael Brenner; Roy A Quinlan
Journal:  Am J Hum Genet       Date:  2006-06-12       Impact factor: 11.025

7.  Increased levels of expression of an NMDARI splice variant in the superior temporal gyrus in schizophrenia.

Authors:  S Le Corre; C G Harper; P Lopez; P Ward; S Catts
Journal:  Neuroreport       Date:  2000-04-07       Impact factor: 1.837

8.  Abnormal object recall and anterior cingulate overactivation correlate with formal thought disorder in schizophrenia.

Authors:  Michal Assaf; Paul R Rivkin; Cheedem H Kuzu; Vince D Calhoun; Michael A Kraut; Karyn M Groth; Michael A Yassa; John Hart; Godfrey D Pearlson
Journal:  Biol Psychiatry       Date:  2005-09-30       Impact factor: 13.382

9.  Differential effects of haloperidol and clozapine on ionotropic glutamate receptors in rats.

Authors:  C F Spurney; S M Baca; A M Murray; G E Jaskiw; J E Kleinman; T M Hyde
Journal:  Synapse       Date:  1999-12-15       Impact factor: 2.562

10.  Expression of excitatory amino acid transporter interacting protein transcripts in the thalamus in schizophrenia.

Authors:  Ibone Huerta; Robert E McCullumsmith; Vahram Haroutunian; José Manuel Giménez-Amaya; James H Meador-Woodruff
Journal:  Synapse       Date:  2006-06-01       Impact factor: 2.562

View more
  41 in total

1.  Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia.

Authors:  Pavel Katsel; William Byne; Panos Roussos; Weilun Tan; Larry Siever; Vahram Haroutunian
Journal:  Neuropsychopharmacology       Date:  2011-01-26       Impact factor: 7.853

2.  Altered fucosyltransferase expression in the superior temporal gyrus of elderly patients with schizophrenia.

Authors:  Toni M Mueller; Stefani D Yates; Vahram Haroutunian; James H Meador-Woodruff
Journal:  Schizophr Res       Date:  2016-10-20       Impact factor: 4.939

3.  Transcriptomic Evidence for Alterations in Astrocytes and Parvalbumin Interneurons in Subjects With Bipolar Disorder and Schizophrenia.

Authors:  Lilah Toker; Burak Ogan Mancarci; Shreejoy Tripathy; Paul Pavlidis
Journal:  Biol Psychiatry       Date:  2018-07-21       Impact factor: 13.382

4.  Glucocorticoid treatment of astrocytes results in temporally dynamic transcriptome regulation and astrocyte-enriched mRNA changes in vitro.

Authors:  Bradley S Carter; Fan Meng; Robert C Thompson
Journal:  Physiol Genomics       Date:  2012-10-30       Impact factor: 3.107

5.  Proteomics as a tool for understanding schizophrenia.

Authors:  Daniel Martins-de-Souza
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-12-31       Impact factor: 2.582

6.  Regional decoupling of N-acetyl-aspartate and glutamate in schizophrenia.

Authors:  Nina V Kraguljac; Meredith A Reid; David M White; Jan den Hollander; Adrienne C Lahti
Journal:  Neuropsychopharmacology       Date:  2012-07-18       Impact factor: 7.853

Review 7.  The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.

Authors:  Wei Hu; Matthew L MacDonald; Daniel E Elswick; Robert A Sweet
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

8.  Glutaminase-deficient mice display hippocampal hypoactivity, insensitivity to pro-psychotic drugs and potentiated latent inhibition: relevance to schizophrenia.

Authors:  Inna Gaisler-Salomon; Gretchen M Miller; Nao Chuhma; Sooyeon Lee; Hong Zhang; Farhad Ghoddoussi; Nicole Lewandowski; Stephen Fairhurst; Yvonne Wang; Agnès Conjard-Duplany; Justine Masson; Peter Balsam; René Hen; Ottavio Arancio; Matthew P Galloway; Holly M Moore; Scott A Small; Stephen Rayport
Journal:  Neuropsychopharmacology       Date:  2009-06-10       Impact factor: 7.853

9.  In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T.

Authors:  Antonio Napolitano; Khalid Shah; Mirjam I Schubert; Veronica Porkess; Kevin C F Fone; Dorothee P Auer
Journal:  Schizophr Bull       Date:  2013-05-13       Impact factor: 9.306

10.  Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia.

Authors:  Dan Shan; Elizabeth K Lucas; Jana B Drummond; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2013-01-26       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.